Medicus Pharma Ltd.: Form 10-Q for the period ended Jun 30, 2025
Filed with the SEC on Aug 11, 2025 and accepted by EDGAR at Aug 11, 2025, 16:24 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2025-06-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Research and development | 3 months2025-04-01 to 2025-06-30 | $1.4m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months2025-01-01 to 2025-06-30 | $3.4m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2025-04-01 to 2025-06-30 | −$6.0m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months2025-01-01 to 2025-06-30 | −$11.1m | us-gaap:OperatingIncomeLoss |
| Net income | 6 months2025-01-01 to 2025-06-30 | −$11.3m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2025-04-01 to 2025-06-30 | −$0.43 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months2025-01-01 to 2025-06-30 | −$0.81 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2025-04-01 to 2025-06-30 | −$0.43 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months2025-01-01 to 2025-06-30 | −$0.81 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2025-04-01 to 2025-06-30 | 14,284,261 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months2025-01-01 to 2025-06-30 | 13,853,305 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 6 months2025-01-01 to 2025-06-30 | −$9.4m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Cash and equivalents | At period end2025-06-30 | $9.7m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2025-06-30 | $11.0m | us-gaap:AssetsCurrent |
| Total assets | At period end2025-06-30 | $11.9m | us-gaap:Assets |
| Current liabilities | At period end2025-06-30 | $8.5m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2025-06-30 | $8.7m | us-gaap:Liabilities |
| Current portion of debt | At period end2025-06-30 | $4.7m | us-gaap:DebtCurrent |
| Shareholders' equity | At period end2025-06-30 | $3.2m | us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest |
Source: SEC EDGAR, the filing index for accession 0001062993-25-014058. Last ingested by Listed: Oct 30, 2026, 16:24 ET. Listed shows no prices and gives no investment advice.